UY28134A1 - Formas de dosificación que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa- reductasa - Google Patents
Formas de dosificación que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa- reductasaInfo
- Publication number
- UY28134A1 UY28134A1 UY28134A UY28134A UY28134A1 UY 28134 A1 UY28134 A1 UY 28134A1 UY 28134 A UY28134 A UY 28134A UY 28134 A UY28134 A UY 28134A UY 28134 A1 UY28134 A1 UY 28134A1
- Authority
- UY
- Uruguay
- Prior art keywords
- inhibitor
- hmg
- coa
- reductasa
- ptec
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una forma de dosificación comprende (1) una despersión sólida amofa que comprende un inhibidor de la proteína de transferencia de ésteres de colesterilo y un polímero ácido potenciador de la concentración, y (2) un inhibidor de la HMG-CoA-reductasa. La dispersión sólida amorfa y el inhibidor de la HMG-CoA-reductasa se combinan en la forma de dosificación de modo que la dispersión sólida amorfa y el inhibidor de la HMG-CoA-reductasa están sustancialmente separados entre sí en la forma de dosificación.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43534502P | 2002-12-20 | 2002-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28134A1 true UY28134A1 (es) | 2004-07-30 |
Family
ID=32682223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28134A UY28134A1 (es) | 2002-12-20 | 2003-12-18 | Formas de dosificación que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa- reductasa |
Country Status (24)
Country | Link |
---|---|
US (1) | US7897175B2 (es) |
EP (1) | EP1581210B1 (es) |
JP (1) | JP2006512359A (es) |
KR (1) | KR20050088190A (es) |
CN (1) | CN1728995A (es) |
AR (1) | AR042534A1 (es) |
AT (1) | ATE389396T1 (es) |
AU (1) | AU2003286372A1 (es) |
BR (1) | BR0317593A (es) |
CA (1) | CA2509688A1 (es) |
CO (1) | CO5590898A2 (es) |
DE (1) | DE60319877T2 (es) |
ES (1) | ES2300628T3 (es) |
GT (1) | GT200300295A (es) |
IL (1) | IL169090A0 (es) |
NL (1) | NL1025070C (es) |
NO (1) | NO20052779L (es) |
PE (1) | PE20040970A1 (es) |
PL (1) | PL377606A1 (es) |
RU (1) | RU2005119176A (es) |
TW (1) | TW200420301A (es) |
UY (1) | UY28134A1 (es) |
WO (1) | WO2004056359A1 (es) |
ZA (1) | ZA200504123B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
KR20040015746A (ko) * | 2001-06-21 | 2004-02-19 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 자가 에멀젼화제제 |
US20030170309A1 (en) * | 2001-06-22 | 2003-09-11 | Babcock Walter C. | Pharmaceutical compositions containing polymer and drug assemblies |
CA2582767C (en) * | 2004-10-25 | 2011-05-24 | Japan Tobacco Inc. | Solid formulation with improved solubility and stability and method for producing said formulation |
EP1819681B1 (en) * | 2004-11-23 | 2009-08-12 | Warner-Lambert Company LLC | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
US20090169583A1 (en) * | 2005-02-08 | 2009-07-02 | Pfizer, Inc. | Solid Adsorbates of Hydrophobic Drugs |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
WO2006129167A1 (en) * | 2005-05-31 | 2006-12-07 | Pfizer Products Inc. | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS |
DK1912626T3 (en) * | 2005-08-08 | 2016-08-01 | Abbvie Deutschland | Dosage forms with improved bioavailability |
ES2571032T3 (es) | 2005-08-08 | 2016-05-23 | Abbvie Deutschland | Composiciones de itraconazol con biodisponibilidad mejorada |
DE102005049293A1 (de) * | 2005-10-15 | 2007-04-26 | Bayer Healthcare Ag | Kombinationspräparate von Salzen oder o-Acetylsalicylsäure |
US7351853B2 (en) * | 2006-01-23 | 2008-04-01 | Albion Advanced Nutrition | Method of manufacturing a granular mineral composition |
KR100791256B1 (ko) * | 2006-03-17 | 2008-01-03 | 주식회사 대웅제약 | 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물 |
US20070269503A1 (en) * | 2006-05-16 | 2007-11-22 | James Walter Burgess | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof |
AU2007300071A1 (en) * | 2006-09-27 | 2008-04-03 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
WO2008065506A2 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein |
AR071706A1 (es) * | 2008-05-15 | 2010-07-07 | Otsuka Pharma Co Ltd | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
MY164729A (en) * | 2010-11-04 | 2018-01-30 | Hoffmann La Roche | A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium |
KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
MX2017002541A (es) * | 2014-08-28 | 2017-11-08 | Dezima Pharma B V | Composicion farmaceutica y combinacion terapeutica que comprende un inhibidor de la proteina de transferencia de colesteril ester e inhibidores de hmg coa reductasa. |
JP2019131472A (ja) * | 2016-05-31 | 2019-08-08 | 興和株式会社 | 医薬組成物 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
JP3254219B2 (ja) * | 1993-01-19 | 2002-02-04 | ワーナー−ランバート・コンパニー | 安定な経口用のci−981製剤およびその製法 |
EP0828495B1 (en) * | 1995-06-01 | 2002-10-30 | G.D. Searle & Co. | Stabilized solid dispersions of misoprostol |
DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
ES2203963T3 (es) * | 1997-05-30 | 2004-04-16 | Osmotica Corp. | Dispositivo osmotico multicapa. |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
US6462091B1 (en) * | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
ES2306646T3 (es) * | 1999-02-09 | 2008-11-16 | Pfizer Products Inc. | Composiciones de farmacos basicos con biodisponibilidad incrementada. |
EP1027888B1 (en) * | 1999-02-10 | 2009-06-10 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
US6531507B1 (en) * | 2000-06-09 | 2003-03-11 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
CA2419406A1 (en) * | 2000-08-15 | 2002-02-21 | Pfizer Products Inc. | Pharmaceutical combinations of torcetrapib and atorvastatin or hydroxy derivatives for the treatment of atherosclerosis, angina and low hdl levels |
US20020077348A1 (en) * | 2000-11-21 | 2002-06-20 | Dean Herbert M. | Dosage unit for cardioprotection |
DE60219307T2 (de) * | 2001-06-12 | 2008-01-10 | Galephar M/F | Oral anzuwendende arzneizusammensetzung enthaltend ein statinderivat |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
AU2003283769A1 (en) * | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
-
2003
- 2003-12-12 AU AU2003286372A patent/AU2003286372A1/en not_active Abandoned
- 2003-12-12 KR KR1020057011269A patent/KR20050088190A/ko not_active Application Discontinuation
- 2003-12-12 CA CA002509688A patent/CA2509688A1/en not_active Abandoned
- 2003-12-12 BR BR0317593-6A patent/BR0317593A/pt not_active IP Right Cessation
- 2003-12-12 PL PL377606A patent/PL377606A1/pl not_active Application Discontinuation
- 2003-12-12 JP JP2004561902A patent/JP2006512359A/ja active Pending
- 2003-12-12 AT AT03777117T patent/ATE389396T1/de not_active IP Right Cessation
- 2003-12-12 DE DE60319877T patent/DE60319877T2/de not_active Revoked
- 2003-12-12 EP EP03777117A patent/EP1581210B1/en not_active Revoked
- 2003-12-12 CN CNA2003801069589A patent/CN1728995A/zh active Pending
- 2003-12-12 ES ES03777117T patent/ES2300628T3/es not_active Expired - Lifetime
- 2003-12-12 WO PCT/IB2003/006087 patent/WO2004056359A1/en active IP Right Grant
- 2003-12-12 RU RU2005119176/15A patent/RU2005119176A/ru not_active Application Discontinuation
- 2003-12-18 NL NL1025070A patent/NL1025070C/nl not_active IP Right Cessation
- 2003-12-18 TW TW092135977A patent/TW200420301A/zh unknown
- 2003-12-18 AR ARP030104713A patent/AR042534A1/es unknown
- 2003-12-18 UY UY28134A patent/UY28134A1/es not_active Application Discontinuation
- 2003-12-18 US US10/739,567 patent/US7897175B2/en not_active Expired - Fee Related
- 2003-12-19 GT GT200300295A patent/GT200300295A/es unknown
-
2004
- 2004-01-05 PE PE2004000021A patent/PE20040970A1/es not_active Application Discontinuation
-
2005
- 2005-05-20 ZA ZA200504123A patent/ZA200504123B/en unknown
- 2005-06-08 NO NO20052779A patent/NO20052779L/no not_active Application Discontinuation
- 2005-06-09 IL IL169090A patent/IL169090A0/en unknown
- 2005-06-17 CO CO05059491A patent/CO5590898A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2005119176A (ru) | 2006-01-20 |
TW200420301A (en) | 2004-10-16 |
BR0317593A (pt) | 2005-11-22 |
KR20050088190A (ko) | 2005-09-02 |
ES2300628T3 (es) | 2008-06-16 |
CA2509688A1 (en) | 2004-07-08 |
WO2004056359A1 (en) | 2004-07-08 |
EP1581210B1 (en) | 2008-03-19 |
US7897175B2 (en) | 2011-03-01 |
GT200300295A (es) | 2004-08-18 |
DE60319877D1 (de) | 2008-04-30 |
IL169090A0 (en) | 2007-07-04 |
DE60319877T2 (de) | 2009-04-30 |
NO20052779L (no) | 2005-08-25 |
PE20040970A1 (es) | 2004-12-14 |
PL377606A1 (pl) | 2006-02-06 |
US20040197398A1 (en) | 2004-10-07 |
EP1581210A1 (en) | 2005-10-05 |
NL1025070C (nl) | 2010-04-06 |
AU2003286372A1 (en) | 2004-07-14 |
CN1728995A (zh) | 2006-02-01 |
CO5590898A2 (es) | 2005-12-30 |
JP2006512359A (ja) | 2006-04-13 |
ZA200504123B (en) | 2006-02-22 |
NL1025070A1 (nl) | 2004-06-22 |
AR042534A1 (es) | 2005-06-22 |
NO20052779D0 (no) | 2005-06-08 |
ATE389396T1 (de) | 2008-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY28134A1 (es) | Formas de dosificación que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa- reductasa | |
WO2004045001A3 (en) | Organic light emitting materials and devices | |
BRPI0413363A (pt) | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
AU2003251529A1 (en) | Planetarium and point light source for the use in same | |
AU2003215175A1 (en) | Fluorescent phospholipase assay, phospholipase a2 inhibitor and stimulator, and the use thereof | |
RU2002107079A (ru) | Вещество, обладающее седативным действием | |
DOP2003000797A (es) | Formas de dosificacion que comprenden un inhibidor de la ptec y un inhbidor de la hmg-coa-reductasa | |
EA200500878A1 (ru) | Кальцилитические соединения | |
PA8593501A1 (es) | Formas de dosificacion que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa-reductasa | |
ES1051849Y (es) | Aerostato publicitario. | |
ES1051373Y (es) | Camilla. | |
ES1052030Y (es) | Embellecedor para calzado y similares. | |
RU2002131660A (ru) | Антидот | |
TH201000963A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201000645A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201001042A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201001377A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201000982A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201001827A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201000553A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201001839A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201002001A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201000899A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา | |
TH201000882A (th) | สิทธิบัตรยังไม่ประกาศโฆษณา |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150511 |